Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
immune checkpoint inhibitor rechallenge after pazopanib treatment in primary pulmonary angiosarcoma a case report
Original title: “Immune checkpoint inhibitor rechallenge after pazopanib treatment in primary pulmonary angiosarcoma: A case report.”
pathological advances and clinical management insights into primary pulmonary myxoid sarcoma harboring the rare ewsr1 creb1 fusion
Original title: “Pathological Advances and Clinical Management Insights into Primary Pulmonary Myxoid Sarcoma Harboring the Rare EWSR1::CREB1 Fusion.”
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry titled "Pulmonary Tuberculosis: Developing Drugs for Treatment." The purpose of this guidance is to assist sponsors in the clinical development of new antibacterial drugs for the treatment of pulmonary tuberculosis (TB). This guidance finalizes the draft guidance of the same title issued on December 15, 2022.
Original title: “Pulmonary Tuberculosis: Developing Drugs for Treatment; Guidance for Industry; Availability”
primary pulmonary epithelioid hemangioendothelioma a clinicopathological analysis of 40 cases
Original title: “[Primary pulmonary epithelioid hemangioendothelioma: a clinicopathological analysis of 40 cases].”